Background & Aims Direct-acting antivirals have become widely used for patients with
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …

Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …

Background: Cirrhosis developing during chronic infection with the hepatitis C virus (HCV)
poses a risk of anticipated liver-related death, therefore representing a dominant indication …

Background Although direct-acting antivirals have been used extensively to treat patients
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …

The management of hepatitis C virus (HCV) infection in patients with decompensated
cirrhosis has evolved dramatically over the past few years mainly due to the availability of all …

Background & Aims Direct-acting antivirals (DAAs) have revolutionized treatment for patients
with chronic hepatitis C virus (HCV) infection, leading to a high rates of sustained virologic …

Direct‐acting antiviral agents (DAAs) are highly effective and well tolerated in patients with
chronic hepatitis C virus infection, including those with compensated cirrhosis. However …

Background & Aims Life expectancy of patients with compensated hepatitis C virus (HCV)
cirrhosis achieving sustained virologic response (SVR) is limited by liver events as …

Chronic infection with the hepatitis C virus (HCV) may lead to hepatic fibrosis and eventually
cirrhosis, at which stage, patients have a substantial risk of liver failure, hepatocellular …

Background Successful antiviral treatment of decompensated hepatitis B with HBV
polymerase inhibitors is associated with improvement of liver function. To what extent liver …